Multi-Disciplinary Monitoring Networks for Mesoscale Underground Experiments: Advances in the Bedretto Reservoir Project.

The Bedretto Underground Laboratory for Geosciences and Geoenergies (BULGG) allows the implementation of hectometer (>100 m) scale in situ experiments to study ambitious research questions. The first experiment on hectometer scale is the Bedretto Reservoir Project (BRP), which studies geothermal exploration. Compared with decameter scale experiments, the financial and organizational costs are significantly increased in hectometer scale experiments and the implementation of high-resolution monitoring comes with considerable risks. We discuss in detail risks for monitoring equipment in hectometer scale experiments and introduce the BRP monitoring network, a multi-component monitoring system combining sensors from seismology, applied geophysics, hydrology, and geomechanics. The multi-sensor network is installed inside long boreholes (up to 300 m length), drilled from the Bedretto tunnel. Boreholes are sealed with a purpose-made cementing system to reach (as far as possible) rock integrity within the experiment volume. The approach incorporates different sensor types, namely, piezoelectric accelerometers, in situ acoustic emission (AE) sensors, fiber-optic cables for distributed acoustic sensing (DAS), distributed strain sensing (DSS) and distributed temperature sensing (DTS), fiber Bragg grating (FBG) sensors, geophones, ultrasonic transmitters, and pore pressure sensors. The network was realized after intense technical development, including the development of the following key elements: rotatable centralizer with integrated cable clamp, multi-sensor in situ AE sensor chain, and cementable tube pore pressure sensor.

Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex.

Statins have been reported to lower the risk of developing Alzheimer's disease; however, the mechanism of this potentially important neuroprotective action is not understood. Lowering cholesterol levels does not appear to be the primary mechanism. Statins have pleiotropic effects in addition to lowering cholesterol, and statins may act on several different pathways involving distinct gene expression patterns that would be difficult to determine by focusing on a few genes or their products in a single study. In addition, gene expression patterns may be specific to a particular statin. To understand the molecular targets of statins in brain, DNA microarrays were used to identify gene expression patterns in the cerebral cortex of mice chronically treated with lovastatin, pravastatin, and simvastatin. Furthermore, brain statin levels were determined using liquid chromatography/tandem mass spectrometry. These studies revealed 15 genes involved in cell growth and signaling and trafficking that were similarly changed by all three statins. Overall, simvastatin had the greatest influence on expression as demonstrated by its ability to modify the expression of 23 genes in addition to those changed by all three drugs. Of particular interest was the expression of genes associated with apoptotic pathways that were altered by simvastatin. Reverse transcription-polymerase chain reaction experiments confirmed the microarray findings. All three drugs were detected in the cerebral cortex, and acute experiments revealed that statins are relatively rapidly removed from the brain. These results provide new insight into possible mechanisms for the potential efficacy of statins in reducing the risk of Alzheimer's disease and lay the foundation for future studies.